title: Inoculation of BCL1 lymphoma cells into CSJL/J F1 mice inhibits acute experimental autoimmune encephalomyelitis.
abstract: T cell vaccination, which protects rodents against experimental autoimmune encephalomyelitis (EAE), has been shown to induce anti-idiotypic response in the T cell compartment. CD5 B cells (B1 cells) are the main source of natural autoantibodies, and are often characterized by high idiotypic connectivity. In this study we examined the possibility that idiotypic connectivity in the B cell compartment may also play a role in the regulation of EAE. We inoculated CSJLF1 mice (H-2d,s) with a CD5 B cell line, the BCL1 lymphoma cells (H-2d), and subsequently induced EAE. The injection of as few as 1,000 BCL1 lymphoma cells significantly blocked the development of EAE. Injection of CD5-negative myeloma cells (SP2) had no effect on the pathogenesis of the disease. Unlike control animals, lymphocytes from BCL1 lymphoma-injected mice significantly proliferate in response to interleukin-5, a growth factor to CD5 B cells. The proliferative response of lymphocytes from BCL1 inoculated mice to mitogenic stimulation was rather unchanged, indicating that no general immunosuppression has been induced by inoculating BCLJ lymphoma. These experiments suggest that CD5 B cells may be involved in the regulation of EAE.
authors.affiliation: Department of Neurology, Hadassah University Hospital, Jerusalem, Israel.
authors.forename: O
authors.initials: O
authors.lastname: Abramsky
authors.forename: D M
authors.initials: DM
authors.lastname: Karussis
authors.forename: R
authors.initials: R
authors.lastname: Mizrachi-Koll
authors.forename: D
authors.initials: D
authors.lastname: Lehmann
mesh_terms: D000208:Acute Disease; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology; D015703:Antigens, CD / Q000276:immunology*; D001402:B-Lymphocytes; D018956:CD5 Antigens; D002460:Cell Line; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000097:blood / Q000276:immunology / Q000517:prevention & control*; D005260:Female; D007165:Immunosuppression Therapy / Q000379:methods; D016219:Immunotherapy, Adoptive / Q000379:methods*; D015848:Interleukin-5 / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D016393:Lymphoma, B-Cell / Q000473:pathology*; D051379:Mice; D008815:Mice, Inbred Strains; D009101:Multiple Myeloma / Q000276:immunology; D014611:Vaccination / Q000379:methods*
chemical_list: D000888:Antibodies, Anti-Idiotypic; D015703:Antigens, CD; D018956:CD5 Antigens; D015848:Interleukin-5